Skip to content
OpenCapital
Get started

Incyte INCY OLUMIANT — Total revenues

Other product segments

JAKAFI
$816.66M+6.9%
OPZELURA
$449.74M+173%
JAKAVI Royalty Revenues
$124.19M+13.2%
NIKTIMVO
$60.31M+66.8%
MINJUVI/MONJUVI
$53.69M+72.5%
ZYNYZ
$49.95M+460%
OLUMIANT Royalty Revenues
$38.48M+14.9%
ICLUSIG
$34.39M+5.1%
PEMAZYRE
$23.42M+5.5%
Milestone and contract revenues
$11.2M+124%
TABRECTA Royalty Revenues
$6.69M+0.9%
Other product royalty revenues
$5.33M+314%

Similar metrics at other companies

ALN
ALNYOXLUMO — Total revenues
$52.12M+11.2%
Bristol-Myers Squibb logo
BMYOpdualag — Total Revenues
$349M+22.9%
United Therapeutics logo
UTHROrenitram — Total revenues
$135.6M+12.3%
Bristol-Myers Squibb logo
BMYOpdivo — Total Revenues
$2.49B-2.9%
Supernus Pharmaceuticals logo
SUPNOxtellar XR — Total revenues
$7.42M-27.2%
Amgen logo
AMGNOtezla — Total revenues
$431M-1.4%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$25.96B+70.1%
Enterprise value$22.01B+64.9%
P/E16.1×-1.4×
P/S4.5×+1.1×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0×0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's olumiant — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's OLUMIANT — total revenues?
Incyte (INCY) reported OLUMIANT — total revenues of $38.5M in Q2 2026.
How has Incyte's OLUMIANT — total revenues changed year-over-year?
Incyte's OLUMIANT — total revenues increased by 14.9% year-over-year, from $33.5M to $38.5M.
What is the long-term trend for Incyte's OLUMIANT — total revenues?
Over 4 years (2021 to 2025), Incyte's OLUMIANT — total revenues has grown at a -10.1% compound annual growth rate (CAGR), from $220.9M to $144.6M.
What does OLUMIANT — total revenues mean?
This metric represents the total gross revenue recognized from the sale or licensing of a specific pharmaceutical product or therapeutic asset. It captures the commercial performance of the drug within the company's portfolio, reflecting market demand and the effectiveness of distribution or partnership agreements. This figure is a primary indicator of the asset's contribution to the firm's top-line financial results.